Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Biomarkers, Tumor
Breast Neoplasms
Capecitabine
Drug-Related Side Effects and Adverse Reactions
Female
Ferredoxin-NADP Reductase
Follow-Up Studies
Genotype
Germ-Line Mutation
Humans
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Polymorphism, Single Nucleotide
Prognosis
Prospective Studies
Quality of Life
authors with profiles
Nancy Jean Cox
Philip Charles Hoffman
Gini Fleming
Mark J. Ratain
Douglas Merkel
Rita Nanda
Olufunmilayo Olopade
Mary Eileen Dolan
Dezheng Huo
Olwen Hahn
Peter H. O'Donnell